What are the indications, recommended dosing schedule, contraindications, and common adverse effects of imipramine in adult patients?

Imipramine: Clinical Overview

Primary Indications

Imipramine is FDA-approved for the treatment of depression in adults and as temporary adjunctive therapy for nocturnal enuresis in children aged 6 years and older. 1

Depression

• Approved for major depressive disorder in adults, adolescents, and elderly patients 1
• Effective in 40-60% of patients with panic disorder and agoraphobia 2, 3
• May be considered for treatment-refractory functional dyspepsia after failure of proton pump inhibitors and prokinetics 4

Childhood Enuresis

• Indicated as temporary adjunctive therapy for nocturnal enuresis in children ≥6 years 2, 1
• Effectiveness ranges from 40-60%, though relapse rates can be as high as 50% 2

Dosing Schedules

Depression in Adults

Hospitalized Patients:

• Initial: 100 mg/day in divided doses 1
• Titrate gradually to 200 mg/day as required 1
• If no response after 2 weeks, increase to 250-300 mg/day 1

Outpatients:

• Initial: 75 mg/day 1
• Increase to 150 mg/day 1
• Doses over 200 mg/day are not recommended 1
• Maintenance: 50-150 mg/day 1

Adolescents and Elderly:

• Initial: 30-40 mg/day 1
• Generally not necessary to exceed 100 mg/day 1
• Start at approximately 50% of the adult starting dose due to increased risk of adverse reactions 5

Childhood Enuresis

• Initial: 25 mg/day given 1 hour before bedtime in children ≥6 years 1
• If inadequate response after 1 week: increase to 50 mg nightly in children <12 years 1
• Children >12 years may receive up to 75 mg nightly 1
• Maximum dose: 2.5 mg/kg/day should not be exceeded 1
• For early-night bedwetters: 25 mg in mid-afternoon, repeated at bedtime may be more effective 1

Dosing Considerations

• Single daily bedtime dosing is therapeutically equivalent to divided doses and is generally preferred by patients 6, 7
• Plasma levels remain relatively stable with once-daily dosing due to long half-life 7
• Therapeutic plasma concentration range for imipramine plus desipramine (active metabolite): 175-300 ng/mL 8

Absolute Contraindications

Imipramine must not be used in the following situations:

• Concomitant use with monoamine oxidase inhibitors (MAOIs) due to risk of hyperpyretic crises or severe convulsive seizures 1
• Minimum 14-day washout period required when switching from an MAOI 1
• During acute recovery period after myocardial infarction 1
• Known hypersensitivity to imipramine or other dibenzazepine compounds 1

High-Risk Situations Requiring Extreme Caution

• Doses >100 mg/day are associated with increased risk of sudden cardiac death, particularly in patients with pre-existing cardiovascular disease 9
• Do not use in patients with Parkinson's disease or dementia with Lewy bodies (due to extrapyramidal side effects) 10
• Severe pulmonary insufficiency, severe liver disease, or myasthenia gravis 10

Mandatory Cardiac and Safety Monitoring

Baseline and Ongoing ECG Monitoring

In Children and Adolescents:

• Obtain baseline ECG before initiating therapy to screen for conduction abnormalities and risk of sudden cardiac death 2, 9
• Repeat ECG monitoring periodically during treatment 9
• ECG changes of unknown significance have been reported at doses of 5 mg/kg/day (twice the maximum recommended dose) 1

In All Patients:

• Obtain prolonged ECG recording to exclude long-QT syndrome in any patient with personal or family history of palpitations, syncope, sudden cardiac death, or unstable arrhythmia 9
• Monitor for QTc prolongation, which can occur with imipramine 10

Suicide Risk Monitoring

• Begin systematic monitoring for suicidal thoughts and behaviors within 1-2 weeks of starting treatment 9
• Highest risk occurs during the first 1-2 months of therapy 9
• Worsening depressive symptoms during this period is a red-flag sign requiring immediate intervention 9

Therapeutic Drug Monitoring (TDM)

• Indicated when non-compliance, drug interactions, or lack of response is suspected despite adequate dosing 8, 9
• Consider TDM if no therapeutic effect at 2.5 mg/kg/day 2, 9
• Target combined plasma concentration (imipramine + desipramine): 175-300 ng/mL 8

Common Adverse Effects

Anticholinergic Effects (Most Common)

• Dry mouth 2, 11, 4, 12
• Constipation 11, 4
• Blurred vision 11, 4
• Urinary hesitancy or retention 11
• Sedation/drowsiness 11, 4
• These effects are more pronounced with imipramine than with secondary-amine tricyclics (nortriptyline, desipramine) 5

Cardiovascular Effects

• Tachycardia/increased heart rate (persistent burden even with long-term stable response) 12
• Orthostatic hypotension 10, 11, 10
• Cardiac arrhythmias (rare but potentially fatal) 2
• QTc prolongation 10

Persistent Long-Term Side Effects

• Sweating (continues to burden patients even after 6-12 months of stable response) 12
• Weight gain (becomes significant with 1-year maintenance treatment) 12
• Sexual dysfunction (though likelihood decreases over time) 12

Discontinuation Rates

• In functional dyspepsia trial: 18% discontinued due to adverse events (dry mouth, constipation, drowsiness, insomnia, palpitations, blurred vision) 4
• In panic disorder: 18% showed marked stimulant side effects on doses as low as 5-75 mg/day 3

Critical Safety Warnings

Overdose and Storage

• Store in locked location away from children; accidental ingestion can be fatal 9
• Ingestion by younger siblings has led to serious or fatal consequences 2
• Prescribe the smallest feasible quantity to reduce overdose risk 9

Drug Interactions

• Fatal cardiac arrhythmia reported in a 10-year-old receiving dexedrine (10 mg) with imipramine (6.9 mg/kg/day) 9
• Discuss this risk before combining with stimulants in children 9

Special Populations

Elderly Patients:

• Initiate at low end of dosing range (typically 10 mg/day for neuropathic pain) 9
• Use slower titration schedules 9
• Higher incidence of cardiac abnormalities and enhanced anticholinergic sensitivity 9
• Monitor closely for confusion, urinary retention, constipation, and falls 9
• Tertiary-amine tricyclics like imipramine are considered potentially inappropriate in elderly per Beers Criteria due to significant anticholinergic effects 5

Renal/Hepatic Impairment:

• Use with caution; consider dose reduction in hepatic impairment 11

Treatment Duration and Discontinuation

• Continue treatment for 4-12 months after first episode of major depression 5
• Patients with recurrent depression may benefit from prolonged treatment 5
• Taper gradually rather than abrupt discontinuation to reduce relapse tendency and limit withdrawal symptoms 2, 11
• For enuresis: institute drug-free period after adequate therapeutic trial with favorable response 1
• Children who relapse when discontinued do not always respond to subsequent treatment 1